N-aryl-5-aminopyrazole: A versatile architecture in medicinal chemistry

Mini-Reviews in Medicinal Chemistry

Volumn 15, Issue 4, 2015, Pages 272-299

  Marinozzi, Maura ^a   Marcelli, Gloria ^a   Carotti, Andrea ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Biologically active compounds; Nitrogen heterocycle; Privileged structure; Pyrazole

Indexed keywords

ADENOSINE A1 RECEPTOR; BRADYKININ B1 RECEPTOR; CANNABINOID RECEPTOR; CYTOCHROME P450; FORMYLPEPTIDE RECEPTOR LIKE 1; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; GLUCOCORTICOID RECEPTOR; METABOTROPIC RECEPTOR 5; MITOGEN ACTIVATED PROTEIN KINASE; N ARYL 5 AMINOPYRAZOLE; PHOSPHOTRANSFERASE INHIBITOR; PYRAZOLE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM FUNCTION; CHEMICAL STRUCTURE; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME ACTIVATION; HUMAN; IC50; MEDICINAL CHEMISTRY; NONHUMAN; POLYMERIZATION; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; PROCEDURES;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; HUMANS; PYRAZOLES;

EID: 84930981756     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666150312154536     Document Type: Article

References (89)

1. Fustero, S.; Sanchez-Rosello, M.; Barrio, P.; Simon-Fuentes, A. From 2000 to Mid-2010: A Fruitful Decade for the Synthesis of Pyrazoles. Chem. Rev., 2011, 111, 6984-7034.
2. Kumar, H.; Saini, D.; Jain, S.; Jain, N. Pyrazole scaffold: A remarkable tool in the development of anticancer agents. Eur. J. Med. Chem., 2013, 70, 248-258.
3. Kumar, V.; Kaur, K.; Kumar Gupta, G.; Sharma, A. K. Pyrazole Containing Natural Products: Synthetic Preview and Biological Significance. Eur. J. Med. Chem., 2013, 69, 735-753.
4. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfieldt, J. J. Med. Chem., 1988, 31, 2235-2246.
5. Duarte, C. D.; Barreiro, E. J.; Fraga, C. A. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev. Med. Chem., 2007, 70, 1108-19.
6. Anwara, H. F.; Mohamed, H. E. Recent developments in aminopyrazole chemistry. Arkivoc, 2009, 198-250.
7. Abu Elmaati, T. M.; El-Taweel, F. M. New Trends in the Chemistry of 5-Aminopyrazoles, J. Heterocyclic Chem., 2004, 41, 109-134.
8. Marinozzi, M.; Marcelli, G.; Carotti, A.; Natalini, B. One-pot, telescoped synthesis of N-aryl-5-aminopyrazoles from anilines in environmentally benign conditions. RSC Adv., 2014, 4, 7019-7023.
9. Dos Santos, M. S.; Oliveira, M. L. V.; Bernardino, A. M. R.; De Léo, R. M.; Amaral, V. F.; De Carvalho, F. T.; Leon, L. L.; Canto-Cavalheiro, M. M. Synthesis and Antileishmanial Evaluation of 1-aryl-4-(4, 5-dihydro-1H-imidazol-2-yl)-1H-pyrazole Derivatives. Bioorg. Med. Chem. Lett., 2011, 21, 7451-7454.
10. Dos Santos Faiões, V.; Leon, L. L.; Canto-Cavalheiro, M. M.; Torres-Santos, E. C.; Bernardino, A. M. R.; Vegi, P. F.; dos Santos, M. S. Effectiveness of Novel 5-(5-amino-1-aryl-1H-pyrazol-4-yl)-1H-tetrazole Derivatives Against Promastigotes and Amastigotes of Lieshmania amazonensis. Chem. Biol. Drug Des., 2014, 83, 272-277.
11. Ashour, H. M. A.; Abdel Wahab, A. E. Synthesis and Biological Evaluation of Novel Pyrazoles and Pyrazolo[3, 4-d]pyrimidines Incorporating a Benzenesulfonamide Moiety. Arch. Pharm. Chem. Life Sci., 2009, 342, 238-252.
12. Goldstein, D. M.; Alfredson, T.; Bertrand, J.; Browner, M. F.; Clifford, K.; Dalrymple, S. A.; Dunn, J.; Freire-Moar, J.; Harris, S.; Labadie, S. S.; La Fargue, J. L.; Lapierre, J. M.; Larrabee, S.; Li, F.; Papp, E.; McWeeney, D.; Ramesha, C.; Roberts, R.; Rotstein, D.; San Pablo, B.; Sjogren, S. B.; So, O.; Talamas, F. X.; Tao, W.; Trejo, A.; Villasenor, A.; Welch, M.; Welch, T.; Weller, P.; Whiteley, P. E.; Young, K.; Zipfel, S. Discovery of S-[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2, 3-dihydroxypropoxy)phenyl]methanone (RO3201195), an Orally Bioavailable and Highly Selective Inhibitor of p38 Map Kinase. J. Med. Chem., 2006, 49, 1562-1575.
13. Kordik, C. P.; Luo, C.; Zanoni, B.; McNally, J. J.; Dax, S. L.; Lovenberg, T. W.; Wilson, S. J.; Reitz, A. B. Aminopyrazoles with High Affinity for the Human Neuropeptide Y5 Receptor. Bioorg. Med. Chem. Lett., 2001, 11, 2283-2286.
14. Berghot, M. A.; Moawad, E. B. Convergent Synthesis and Antibacterial Activity of Pyrazole and Pyrazoline Derivatives of Diazepam. Eur. J. Pharm. Sci., 2003, 20, 173-179.
15. Thaher. B. A.; Arnsmann, M.; Totzke, F.; Ehlert, J. E.; Kubbutat, M. H. G.; Schächtele, C.; Zimmermann, M. O.; Koch, P.; Boeckler, F. M.; Laufer, S. A. Tri-and Tetrasubstituted Pyrazole Derivates: Regioisomerism Switches Activity from p38MAP Kinase to Important Cancer Kinases. J. Med. Chem., 2012, 55, 961-965.
16. Bagley, M. C.; Davis, T.; Dix, M. C.; Murziani, P. G. S.; Rokicki, M. J.; Kipling; D. Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38MAPK inhibitor RO3201195 for study in Werner syndrome cells, Bioorg. Med. Chem. Lett., 2008, 18, 3745-3748.
17. Minami, N.; Sato, M.; Hasumi, K.; Yamamoto, N.; Keino, K.; Matsui, T.; Kanada, A.; Ohta, S.; Saito, T.; Sato, S.; Asagarasu, A.; Doi, S.; Kobayashi, M.; Sato, J.; Asano, H. Preparation of Aminopyrazole Derivatives as p38 Mitogen-Activated Protein (p38MAP) Kinase Inhibitors. Patent 2000, WO2000039116A1.
18. Dumas, J.; Sibley, R.; Riedl, B.; Monahan, M. K.; Lee, W.; Lowinger, T. B.; Redman, A. M.; Johnson, J. S.; Kingery-Wood, J.; Scott, W. J.; Smith, R. A.; Bobko, M.; Schoenleber, R.; Ranges, G. E.; Housley, T. J.; Bhargava, A.; Wilhelm, S. M.; Shrikhande, A. Discovery of a New Class of p38 Kinase Inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 2047-2050.
19. Dumas, J.; Hatoum-Mokdad, H.; Sibley, R.; Riedl, B.; Scott, W. J.; Monahan, M. K.; Lowinger, T. B.; Brennan, C.; Natero, R.; Turner, T.; Johnson, J. S.; Schoenleber, R.; Bhargava, A.; Wilhelm, S. M.; Housley, T. J.; Ranges, G. E.; Shrikhande, A. 1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 2051-2054.
20. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate. J. Med. Chem., 2002, 45, 2994-3008.
21. Pargellis, C. A.; Tong, L.; Churchill, L.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 map kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol., 2002, 9, 268-272.
22. Regan, J.; Capolino, A.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Hickey, E.; Kroe, R. R.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C. A.; Swinamer, A.; Torcellini, C.; Tsang, M.; Moss, N. Structure-Activity Relationships of the p38α MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-ylethoxy) naphthalene-1-yl]urea (BIRB 796). J. Med. Chem., 2003, 46, 4676-4686.
23. Branger, J.; van den Blink, B.; Weijer, S.; Madwed, J.; Bos, C. L.; Gupta, A.; Polmar, S. H.; Olszyna, D. P.; Hack, C. E.; van Deventer, S. J. H.; Peppelenbosch, M. P.; van der Poll, T. Antiinflammatory effects of a p38 mitogen activated protein kinase inhibitor, BIRB 796 BS, during human endotexemia. J. Immunol., 2002, 168, 4070-4077.
24. Wood, C. C.; Yong, C.-L.; Madwed, J. B.; Gupta, A. Safety, pharmacokinetics and pharmacodynamics of oral p38 MAP kinase inhibitor (BIRB 796 BS), administered once daily for 7 days. J. Allergy Clin. Immunol., 2002, 109, S321.
25. Schreiber, S.; Feagan, B.; D'Haens, G.; Colombel, J.-F.; Geboes, K.; Yurcov, M.; Isakov, V.; Golovenko, O.; Bernstein, C. N.; Ludwig, D.; Winter, T.; Meier, U.; Yong, C.; Steffgen, J. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebocontrolled trail. Clin. Gastroenterol. Hepat., 2006, 4, 325-334.
26. Goldstein, D. M. The discovery of RO3201105, a novel and selective inhibitor of p38 kinase. Fifth World Conference on Inflammation, Edingburgh, Scotland, September 22-26, 2001; Abstract 12/02.
27. Das, J.; Moquin, R. V.; Pitt, S.; Zhang, R.; Ren Shen, D.; McIntyre, K. W.; Gillooly, K.; Doweyko, A. M.; Sack, J. S.; Zhang, H.; Kiefer, S. E.; Kish, K.; McKinnon, M.; Barrish, J. C. Dodd, J. H.; Schieven, G. L.; Leftheris, K. Pyrazolo-pyrimidines: A novel heterocyclic scaffold for potent and selective p38α inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 2652-2657.
28. Das, J.; Moquin, R. V.; Dyckman, A. J.; Li, T.; Pitt, S.; Zhang, R.; Ren Shen, D.; McIntyre, K. W.; Gillooly, K.; Doweyko, A. M.; Newitt, J. A.; Sack, J. S.; Zhang, H.; Kiefer, S. E.; Kish, K.; McKinnon, M.; Barrish, J. C.; Dodd, J. H.; Schieven, G. L.; Leftheris, K. 5-Amino-pyrazole as potent and selective p38α inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 6886-6889.
29. Millan, D. S.; Bunnage, M. E.; Burrows, J. L.; Butcher, K. J.; Dodd, P. G.; Evans, T. J.; Fairman, D. A.; Hughes, S. J.; Kilty, I. C.; Lemaitre, A.; Lewthwaite, R. A.; Mahnke, A.; Mathias, J. P.; Philip, J.; Smth, R. T.; Stefaniak, M. H.; Yeadon, M.; Phillips, C. Design and Synthesis of Inhalated p38 Inhibitors for the Treatment of Obstructive Pulmonary Disease. J. Med. Chem., 2011, 54, 7797-7814.
30. McClure, K. F.; Abramov, Y. A.; Laiord, E. R.; Barberia, J. T.; Cai, W.; Carty, T. J.; Cortina, S. R.; Danley, D. E.; Dipesa, A. J.; Donahue, K. M.; Dombroski, M. A.; Alliott, N. C.; Gabel, C. A.; Han, S.; Hynes, T. R.; LeMotte, P. K.; Mansour, M. N.; Marr, E. S.; Letavic, M. A.; Pandit, J.; Ripin, D. B.; Sweeney, F. J.; Tan, D.; Tao, Y. Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase. J. Med. Chem., 2005, 48, 5728-5737.
31. Montalban, A. G.; Boman, E.; Chang C.-D.; Ceide, S. C.; Dahl, R.; Dalesandro, D.; Delaet, N. G. J.; Erb, E.; Ernst, J. T.; Gibbs, A.; Kahl, J.; Kessler, L.; Lundström, J.; Miller, S.; Nakanishi, H.; Roberts, E.; Saiah, E.; Sullivan, R.; Wang, Z.; Larson, C. J. The design and synthesis of novel α-ketoamide-based p38 MAP kinase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 1772-1777.
32. Tecle, H.; Feru, F.; Liu, H.; Kuhn, C.; Rennie, G.; Morris, M.; Shao, J.; Cheng, A. C.; Gikunju, D.; Miret, J.; Coli, R.; Xi, S.; Clugston, S. L.; Low, S.; Kazmirski, S.; Ding, Y.-H.; Cao, Q.; Johnson, T. L.; Deshmukh, G. D.; DiNitto, J. P.; Wu, J. C.; English, J. M. The Design, Synthesis, and Potential Utility of Fluorescence Probes that target DFG-out Conformation of p38α for High Throughput Screening Binding Assay. Chem. Biol. Drug Des., 2009, 74, 547-559.
33. Flynn, D. L.; Petillo, P. A. WO 2004/061084.
34. Flynn, D. L.; Petillo, P. A. WO 2007/008917.
35. Flynn, D. L.; Petillo, P. A. WO 2008/0248548.
36. Swann, S. L.; Merta, P. J.; Kifle, L.; Groebe, D.; Sarris, K.; Hajduk, P. J.; Sun, C. Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α. Bioorg. Med. Chem. Lett., 2010, 20, 5787-5792.
37. Lacerda, R. B.; da Silva, L. L.; de Lima, C. K. F.; Miguez, E.; Miranda, A. L. P.; Laufer, S. A.; Barreiro, E. J.; Fraga, C. A. M. Discovery of Novel Orally Active Anti-Inflammatory NPhenylpyrazolyl-N-Glycinyl-Hydrazone Derivatives That Inhibit TNF-α Production. PLOS One, 2012, 7, e46925.
38. Kilty, I.; Green, M. P.; Bell, A. S.; Brown, D. G.; Dodd, P. G.; Hewson, C.; Hughes, S. J.; Phillips, C.; Ryckmans, T.; Smith, R. T.; van Hoorn, W. P.; Cohen, P.; Jones, L. H. TAK1 Inhibition in the DFG-Out Conformation. Chem. Biol. Drug Des., 2013, 82, 500-505.
39. Liu, H.; Kuhn, C.; Feru, F.; Jacques, S. L.; Deshmukh, G. D.; Ye, P.; Rennie, G. R.; Johnson, T.; Kazmirski, S.; Low, S.; Coli, R.; Ding, Y.-H.; Cheng, A. C.; Tecle, H.; English, J. M.; Stanton, R.; Wu, J. C. Enhanced selectivity profile of pyrazole-urea based DFG-out p38α inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 4885-4891.
40. Li, X.; Zhou, X.; Zhang, J.; Wang, L.; Long, L.; Zheng, Z.; Li, S.-; Zhong, W. Synthesis and biological evaluation of chromenylurea and chromanylurea derivatives as anti-TNF-α agents that target the p38 MAPK pathway. Molecules, 2014, 19, 2004-2028.
41. Liu, Y. X.; Liu, S. H.; Li, Y. H.; Song, H. B.; Wang, Q. M. Synthesis and biological evaluation of arylhydrazinocyanoacrylates and N-aryl pyrazolecarboxylates. Bioorg. Med. Chem. Lett. 2009, 19, 2953-2956.
42. Li, S.; Zhou, Y.; Lu, W.; Zhong, Y.; Song, W.; Liu, K.; Huang, J.; Zhao, Z.; Xu, Y.; Liu, X.; Li, H. Identification of Inhibitors against p90 Ribosomal S6 Kinase 2 (RSK2) through Structure-Based Virtual Screening with the Inhibitor-Constrained Refined Homology Model. J. Chem. Inf. Model., 2011, 51, 2939-2947.
43. Getlik, M.; Grütter, C.; Simard, J. R.; Klüter, S.; Rabiller, M.; Rode, H. B.; Robubi, R.; Rauth, D. Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc. J. Med Chem. 2009, 52, 3915-3926.
44. Niculescu-Duvaz, D.; Gaulon, C.; Dijkstra, H. P.; Niculescu-Duvaz, I.; Zambon, A.; Menard, D.; Suijkerbuijk, B. M.; Nourry, A.; Davies, L.; Manne, H.; Friedlos, F.; Ogilvie, L.; Hedley, D.; Whittaker, S.; Kirk, R.; Gill, A.; Taylor, R. D.; Raynaud, F. I.; Moreno-Farre, J.; Marais, R.; Springer, C. J. Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). J. Med. Chem., 2009, 52, 2255-2264.
45. Menard, D.; Niculescu-Duvaz, I.; Dijkstra, H. P.; Niculescu-Duvaz, D.; Suijkerbuijk, B. M.; Zambon, A.; Nourry, A.; Roman, E.; Davies, L.; Manne, H. A.; Friedlos, F.; Kirk, R.; Whittaker, S.; Gill, A.; Taylor, R. D.; Marais, R.; Springer, C. J. Novel potent BRAF inhibitors: toward 1nM compounds through optimization of the central phenyl ring. J. Med. Chem., 2009, 52, 3881-3891.
46. Liao, J. J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem., 2007, 50, 409-424.
47. Arnaud Nourry, Alfonso Zambon, Lawrence Davies, Ion Niculescu-Duvaz, Harmen P. Dijkstra, Delphine Menard, Catherine Gaulon, Dan Niculescu-Duvaz, Bart M. J. M. Suijkerbuijk, Frank Friedlos, Helen A. Manne, Ruth Kirk, Steven Whittaker, Richard Marais, Caroline J. Springer J. Med. Chem., 2010, 53, 1964-1978.
48. Zambon, A.; Ménard, D.; Suijkerbuijk, B. M. J. M.; Niculescu-Duvaz, I.; Whittaker, S.; Nicolescu-Duvaz, D.; Nourry, A.; Davies, L.; Manne, H. A.; Lopes, F.; Preece, N.; Hedley, D.; Ogilvie, L. M.; Kirk, R.; Marais, R.; Springer, C. J. Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors. J. Med. Chem., 2010, 53, 5639-5655.
49. Malancona, S.; Altamura, S.; Filocamo, G.; Kinzel, O.; Martin Hernando, J. I.; Rowley, M.; Scarpelli, R.; Steinkühler, C.; Jones, P. Identification of MK-5710 ((8aS)-8a-methyl-1, 3-dioxo-2-[(1S, 2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimid azo[1, 5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, Part 1. Bioorg. Med. Chem. Lett., 2011, 21, 4422-4428.
50. Kinzel, O.; Alfieri, A.; Altamura, S.; Brunetti, M.; Bufali, S.; Colaceci, F.; Ferrigno, F.; Filocamo, G.; Fonsi, M.; Gallinari, P.; Malancona, S.; Martin Hernando, J. I.; Monteagudo, E.; Orsale, M. V.; Palumbi, M. C.; Pucci, V.; Rowley, M.; Sasso, R.; Scarpelli, R.; Steinkühler, C.; Jones, P. Identification of MK-5710 ((8aS)-8amethyl-1, 3-dioxo-2-[(1S, 2R)-2-phenylcyclo-propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1, 5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, Part 2. Bioorg. Med. Chem. Lett., 2011, 21, 4429-4435.
51. Cheng, K.-M.; Huang, Y.-Y.; Huang, J.-J.; Kaneko, K.; Kimura, M.; Takayama, H.; Juang, S.-H.; Wong, F. F. Synthesis and antiproliferative evaluation of N, N-disubstituted-N'-[1-aryl-1Hpyrazol-5-yl]methnimidamides. Bioorg. Med. Chem. Lett., 2010, 20, 6781-6784.
52. Nitelescu, G. M.; Draghici, C.; Missir, A. V. Synthesis of new pyrazole derivatives and their anticancer evaluation. Eur. J. Med. Chem., 2010, 45, 4914-4919.
53. Sekkak, H.; Rakib, E. M.; Abdelouahid, M. A.; Hafid, A.; Malki, A. E. Synthesis and in Vitro Cytotoxic Activity of Novel Pyrazole-3, 4-dicarboxylates. Int. J. Org. Chem., 2013, 3, 37-41.
54. Santos, M. S.; Gomes, A. O.; Bernardino, A. M. R.; Souza, M. C.; Khan, M. A.; Brito, M. A.; Castro, H. C.; Abreu, P. A.; Rodrigues, C. R.; Léo, R. M. M.; Leon, L. L.; Canto-Cavalheiro, M. M. Synthesis and antileishmanial activity of new 1-aryl-1H-pyrazole-4-carboxamides derivatives. J. Braz. Chem. Soc., 2011, 22, 352-358.
55. Charret, K. S.; Rodrigues, R. F.; Bernardino, A. M. R.; Gomes, A. O.; Carvalho, A. V.; Canto-Cavalheiro, M. M.; Leon, L. L.; Amaral, V. F. Effect of oral treatment with pyrazole carbohydrazide derivatives against murine infection by Leishmania amazonensis. Am. J. Trop. Med. Hyg,. 2009, 80, 568-573.
56. Bernardino, A. M. R.; Gomes, A. O.; Charret, K. S.; Freitas, A. C.; Machado, G. M.; Canto-Cavalheiro, M. M.; Leon, L. L.; Amaral, V. F. Synthesis and leishmanicidal activities of 1-(4-X-phenyl)-N'-[(4-Y-phenyl)methyl-1H-pyrazole-4-carbohydrazides. Eur. J. Med. Chem., 2006, 41, 80-87.
57. Mello, H.; Echevarria, A.; Bernardino, A. M. R.; Canto-Cavalheiro, M. M.; Leon, L. L. Antileishmanial pyrazolopyridine derivatives: synthesis and structure-activity relationship analysis. J. Med. Chem., 2004, 47, 5427-5432.
58. El-Emary, T. I.; Al-Muaikel, N.; Moustafa, O. S. Synthesis and antimicrobial Activity of Some New Heterocycles Based on 3-Methyl-1-phenyl-5-benzenesulfonamido pyrazole. Phosphorus Sulfur and Silicon, 2002, 177, 195-201.
59. Emad Azab, M.; Youssef, M. M.; El-Bordany, E. A. Synthesis and Antibacterial Evaluation of Novel Heterocyclic Compounds Containing a Sulfonamido Moiety. Molecules, 2013, 18, 832-844.
60. Berghot, M. A.; Moawad, E. B. Convergent Synthesis and Antibacterial Activity of Pyrazole and Pyrazoline Derivatives of Diazepam. Eur. J. Pharm. Sci., 2003, 20, 173-179.
61. Kane, Jr J. L:; Hirth, B. H.; Liang, B.; Gourlie, B. B.; Nahill, S.; Barsomian, G. Ureas of 5-Aminopyrazole and 2-Aminothiazole Inhibit Growth of Gram-Positive Bacteria. Bioorg. Med. Chem. Lett., 2003, 13, 4463-4466.
62. Rahimizaded, M.; Pordel, M.; Bakavoli, M.; Rezaeian, S.; Sadeghian, A. Synthesis and antibacterial activity of some new derivatives of pyrazole. World J. Microbiol. Biotechnol., 2010, 26, 317-321.
63. Aggarwal, R.; Kumar, V.; Kumar Gupta, G. Synthesis of Some New 3, 5-diamino-4-(4'-fluorophenylazo)-1-aryl/heteroarylpyrazoles as Antimicrobial Agents. Med. Chem. Res., 2013, 22, 3566-3573.
64. Matysiak, J.; Niewiadomy, A. Synthesis and Antimycotic Activity of N-azolyl-2, 4-dihydroxythiobenzamides. Bioorg. Med. Chem., 2003, 11, 2285-2291.
65. Romagnoli, C.; Mares, D.; Bruni, A.; Andreotti, E.; Manfrini, M.; Vicentini, C. B. Antifungal Activity of 5 New Synthetic Compounds vs. Trichophyton rubrum and Epidermophyton floccosum. Mycopathologia, 2001, 153, 129-132.
66. Mizuhara, T.; Kato, T.; Hirai, A.; Kurihara, H.; Shimada, Y.; Taniguchi, M.; Maeta, H.; Togami, H.; Shimura, K.; Matsuoka, M.; Okazaki, S.; Takeuchi, T.; Ohno, H.; Oishi, S.; Fujii, N. Structureactivity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agents. Bioorg. Med. Chem. Lett., 2013, 23, 4557-4561.
67. Barker, M.; Clackers, M.; Demaine, D. A.; Humphreys, D.; Johnston, M. J.; Jones, H. T.; Pacquet, F.; Pritchard, J. M.; Shanahan, S. E.; Skone, P. A.; Vinader, V. M.; Uings, I.; McLay, I. M.; Macdonald, S. J. F. Design and Synthesis of New Non-Steroidal Glucocorticoid Modulators through Application of an "Agreement Docking" Method. J. Med. Chem., 2005, 48, 4507-4510.
68. Barker, M.; Clackers, M.; Copley, R.; Demaine, D. A.; Humphreys, D.; Inglis, G. G. A.; Johnston, M. J.; Jones, H. T.; Haase, M. V.; House, D.; Loiseau, R.; Nisbet, L.; Pacquet, F.; Skone, P. A.; Shanahan, S. E.; Tape, D.; Vinader, V. M.; Washington, M.; Uings, I.; Upton, R.; McLay, I. M.; Macdonald, S. J. F. Dissociated Nonsteroidal Glucocorticoid Receptor Modulators; Discovery of the Agonist Trigger in a Tetrahydronaphthalene-Benzoxazine Series. J. Med. Chem., 2006, 49, 4216-4231.
69. Clackers, M.; Coe, D. M.; Demaine, D. A.; Hardy, G. W.; Humphreys, D.; Inglis, G. G. A.; Johnston, M. J.; Haydn, T. J.; Haase, M. V.; House, D.; Loiseau, R.; Minick, J. D.; Skone, P. A.; Uings, I.; Upton, R.; McLay, I. M.; Macdonald, S. J. F. Non-Steroidal Glucocorticoid Agonists-The Discovery of Aryl Pyrazoles as ARing Mimetics. Bioorg. Med. Chem. Lett., 2007, 17, 4737-4745.
70. Biggadike, K.; Boudjelal, M.; Clackers, M.; Coe, D. M.; Demaine, D. A.; Hardy, G. W.; Humphreys, D.; Inglis, G. G. A.; Johnston, M. J.; Jones, H. T.; House, D.; Loiseau, R.; Needham, D.; Skone, P. A.; Uings, I.; Veitch, G.; Weingaarten, G. G.; McLay, I. M.; Macdonald, S. J. F. Nonsteroidal glucorticoid agonists: tetrahydronaphtalenes with alternative steroidal A-ring mimetics possessing dissociated (transrepression/transactivation) efficacy selectivity. J. Med. Chem., 2007, 50, 6519-6534.
71. Barnett, H. A.; Coe, D. M.; Cooper, T. W. J.; Torquil, I. J.; Haydn, T. J.; Macdonald, S. F. J.; McLayc, I. M.; Rayner, N.; Sasse, R. Z.; Shipley, T. J.; Skone, P. A.; Somers, I. G.; Taylor, S.; Uings, I. J.; Woolven, J. M.; Weingarten, J. J. Aryl Aminopyrazole Benzamides as Oral Non-Steroidal Selective Glucocorticoid Receptor Agonists. Bioorg. Med. Chem. Lett., 2009, 19, 158-162.
72. Dressen, D.; Garofalo, A. W.; Hawkinson, J.; Hom, D.; Jagodzinski, J.; Marugg, J. L.; Neitzel, M. L.; Pleiss, M. A.; Szoke, B.; Tung, J. S.; Wone, D. W. G.; Wu, J.; Zhang, H. Preparation and Optimization of a Series of 3-Carboxamido-5-Phenacylaminopyrazole Bradykinin B1 Receptor Antagonists. J. Med. Chem., 2007, 50, 5161-5167.
73. Morley, A. D.; Cook, A.; King, S.; Roberts, B.; Lever, S.; Weaver, R.; Macdonald, C.; Unitt, J.; Fagura, M.; Phillips, T.; Lewis, R.; Wenlock, M. Discovery of Pyrazoles as Novel FPR1 Antagonists. Bioorg. Med. Chem. Lett., 2011, 21, 6456-6460.
74. Griebenow, N.; Bärfacker, L.; Meier, H.; Schneider, D.; Teusch, N.; Lustig, K.; Kast, R.; Kolkhof, P. Identification and Optimization of Substituted 5-Aminopyrazoles as Potent and Selective Adenosine A1 Receptor Antagonists. Bioorg. Med. Chem. Lett., 2010, 20, 5891-5894.
75. Rehse, K.; Kotthaus, J.; Khadembashi, L. New 1H-Pyrazole-4-Carboxamides with Antiplatelet Activity. Arch. Pharm. (Weinheim), 2009, 342, 27-33.
76. Mancy, A.; Dijols, S.; Poli, S.; Guengerich, P.; Mansuy, D. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry, 1996, 35, 16205-16212.
77. Ha-Duong, N. T.; Dijols, S.; Marques-Soares, C.; Minoletti, C.; Dansette, P. M.; Mansuy, D. Synthesis of Sulfaphenazole Derivatives and Their Use as Inhibitors and Tools for Comparing the Active Sites of Human Liver Cytochromes P450 of the 2C Subfamily. J. Med. Chem., 2001, 44, 3622-3631.
78. Lindsley, C. W.; Wisnoski, D. D.; Leister, W. H.; O'Brien, J. A.; Lemaire, W.; Williams, Jr., D. L.; Burno, M.; Sur, C.; Kinney, G. G.; Pettibone, D. J.; Tiller, P. R.; Smith, S.; Duggan, M. E.; Hartman, G. D.; Conn, P. J.; Huff, J. R. Discovery of Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 5 from a Series of N-(1, 3-Diphenyl-1H-pyrazol-5-yl)benzamides That Potentiate Receptor Function in vivo. J. Med. Chem., 2004, 47, 5825-5828.
79. Chen, Y.; Nong, Y.; Goudet, C.; Hemstapat, K.; de Paulis, T.; Pin, J.-P.; Conn, P. J. Interaction of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 with the Negative Allosteric Antagonist Site Is Required for Potentiation of Receptor Responses. Mol. Pharmacol., 2007, 71, 1389-1398.
80. Chen, Y.; Goudet, C.; Pin, J.-P.; Conn, P. J. N-{4-Chloro-2-[(1, 3-dioxo-1, 3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) Acts through a Novel Site as a Positive Allosteric Modulator of Group 1 Metabotropic Glutamate Receptors. Mol. Pharmacol., 2008, 73, 909-918.
81. Zou, M.-F.; Cao, J.; Rodriguez, A. L.; Conn, P. J.; Newman, A. H. Design and synthesis of substituted N-(1, 3-diphenyl-1H-pyrazol-5-yl)benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5. Bioorg. Med. Chem. Lett., 2011, 21, 2650-2654.
82. Kaufmann, K.; Romaine, I.; Days, E.; Pascual, C.; Malik, A.; Yang, L.; Zou, B.; Du, Y.; Sliwoski, G.; Morrison, R. D.; Denton, J.; Niswender, C. M.; Daniels, J. S.; Sulikowski, G. A.; Xie, X. S.; Lindsley, C. W.; Weaver, C. D. ML297 (VU0456810), the First Potent and Selective Activator of the GIRK Potassium Channel, Displays Antiepileptic Properties in Mice. ACS Chem. Neurosci., 2013, 4, 1278-1286.
83. i/o-linked G proteincoupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. Mol. Pharmacol., 2008, 73, 1213-1224.
84. Wen, W.; Wu, W.; Romaine, I. M.; Kaufmann, K.; Du, Y.; Sulikowski, G. A.; Weaver, C. D.; Lindsley, C. W. Discovery of "Molecular Switches" within a GIRK Activator Scaffold That Afford Selective GIRK Inhibitors. Bioorg. Med. Chem. Lett., 2013, 23, 4562-4566.
85. Sam, A. H.; Salem, V.; Ghatei, M. A. Rimonabant: From RIO to Ban. J. Obes. 2011, doi: 10. 1155/2011/432607.
86. Silvestri, R.; Cascio, M. G.; La Regina, G.; Piscitelli, F.; Lavecchia, A.; Brizzi, A.; Pasquini, S.; Botta, M.; Novellino, E.; Di Marzo, V.; Corelli, F. Synthesis, Cannabinoid Receptor Affinity, and Molecular Modeling Studies of Substituted 1-Aryl-5-(1Hpyrrol-1-yl)-1H-pyrazole-3-carboxamides. J. Med. Chem., 2008, 51, 1560-1576.
87. 2 Receptor Ligands. Eur. J. Med. Chem., 2011, 46, 5641-5653.
88. Ahmed, H. H.; Elmegeed, G. A.; el-Sayed, S. M.; Abd-Elhalim, M. M.; Shousha, W. G.; Shafic, R. W. Potent Neuroprotective Role of Novel Melatonin Derivatives for Management of Central Neuropathy Induced by Acrylamide in Rats. Eur. J. Med. Chem., 2010, 45, 5452-5459.
89. Reiter, R. J.; Manchester, L. C.; Tan, D.-X. Neurotoxins: Free Radical Mechanisms and Melatonin Protection. Curr. Neuropharmacol., 2010, 8, 194-210.